HIF prolyl hydroxylase domain 2 (PHD2 / EGLN1)

Class

Oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor)

Pathway

HIF stabilization -> endogenous EPO induction -- erythropoiesis pathway (anemia of non-dialysis CKD)

Prolyl hydroxylase domain protein 2 (PHD2, also called EGLN1) is an oxygen-sensing enzyme that continuously marks hypoxia-inducible factor (HIF), a transcription factor, for degradation when oxygen is plentiful. Under low-oxygen conditions, PHD2 activity falls, HIF accumulates, and it activates genes that help the body adapt to hypoxia, including the gene for erythropoietin (EPO), the hormone that stimulates red blood cell production in bone marrow. Small-molecule inhibitors of PHD2 pharmacologically mimic this hypoxic state even when oxygen levels are normal, stabilizing HIF and inducing the body's own EPO production along with supporting changes in iron handling needed for hemoglobin synthesis. This approach is relevant to anemia associated with chronic kidney disease, where diseased kidneys lose the capacity to produce adequate endogenous EPO. Rather than supplying an external protein, an oral HIF prolyl hydroxylase inhibitor (HIF-PHI) works upstream by reactivating the body's natural erythropoiesis pathway. Because HIF signaling also touches angiogenesis, metabolism, and other adaptive responses to hypoxia, this class of therapy sits at the intersection of endocrinology, nephrology, and hematology, and its broader relevance depends on how selectively it engages the erythropoiesis-related consequences of HIF stabilization versus other hypoxia-response genes.